drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T)
drug_description
Autologous anti-CD19 CAR T-cell therapy with CD3ΞΆ/4-1BB costimulation used for B-cell malignancies including DLBCL.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Tisagenlecleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous anti-CD19 CAR T cells incorporating CD3zeta signaling and a 4-1BB costimulatory domain; upon binding CD19 on B cells, they activate, expand, release cytotoxic mediators and cytokines, and kill malignant CD19+ B cells.
drug_name
Tisagenlecleucel (tisa-cel)
nct_id_drug_ref
NCT05675982